Perjeta (pertuzumab) / Roche 
Welcome,         Profile    Billing    Logout  
 80 Diseases   252 Trials   252 Trials   6382 News 


«12...3435363738394041424344...8586»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal:  Inflammatory breast cancer with excellent response to pembrolizumab-chemotherapy combination: A case report. (Pubmed Central) -  May 25, 2022   
    We herein report a case of stage IIIC triple-negative IBC treated with pembrolizumab plus chemotherapy based neoadjuvant therapy with a complete clinical and complete pathological response. This is the first case of triple-negative IBC treated with this regimen reported in the literature, thereby providing clinical data on the tolerability and efficacy of pembrolizumab plus chemotherapy based neoadjuvant regimen for the treatment of IBC.
  • ||||||||||  Inluriyo (imlunestrant) / Eli Lilly
    Trial completion date, Monotherapy:  EMBER: A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (clinicaltrials.gov) -  May 20, 2022   
    P1a/1b,  N=500, Recruiting, 
    This is the first case of triple-negative IBC treated with this regimen reported in the literature, thereby providing clinical data on the tolerability and efficacy of pembrolizumab plus chemotherapy based neoadjuvant regimen for the treatment of IBC. Trial completion date: Apr 2023 --> Dec 2023
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Trial completion date:  Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa (clinicaltrials.gov) -  May 19, 2022   
    P2,  N=23, Active, not recruiting, 
    Trial completion date: Apr 2023 --> Dec 2023 Trial completion date: Mar 2022 --> Mar 2023
  • ||||||||||  Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Perjeta (pertuzumab) / Roche
    Retrospective data, Journal, HEOR:  Comparative effectiveness and tolerability of targeted agents combined with chemotherapy in patients with HER2-positive gastroesophageal cancer: A network meta-analysis. (Pubmed Central) -  May 19, 2022   
    The trastuzumabderuxtecan (TraD) and pertuzumab plus trastuzumab and chemotherapy (PerTraChemo) regimens were considered to have high effectiveness but low tolerability...As the second- or third-line therapy, TraD and lapatinib plus chemotherapy (LapChemo) had high effectiveness and moderate tolerability...TraD had relative advantages as the second- or third-line therapy and in the IHC3 + population. PerTraChemo is a potential first-line therapy, but it requires further confirmation because the JACOB phase III clinical trial failed to confirm the superiority of PerTraChemo over TraChemo with regard to OS.
  • ||||||||||  Tukysa (tucatinib) / Pfizer, Kisqali (ribociclib) / Novartis, Perjeta (pertuzumab) / Roche
    Enrollment open:  UCLA B-13: Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer (clinicaltrials.gov) -  May 12, 2022   
    P1b,  N=18, Recruiting, 
    As ADCC is a potential critical quality attribute of Perjeta®, the glycosylation of Perjeta® and its biosimilars should be tightly monitored and controlled. Not yet recruiting --> Recruiting
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Review, Journal, BRCA Biomarker, PD(L)-1 Biomarker, IO biomarker:  Landmark trials in the medical oncology management of metastatic breast cancer. (Pubmed Central) -  Apr 30, 2022   
    Numerous obstacles still exist in treating MBC, especially for patients whose disease develops resistance to available agents. Future research is eagerly awaited to address the optimal sequence or combination of therapies and to identify better biomarkers to guide precision medicine.
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
    New P2 trial:  SHR-A1811-II-202: A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer (clinicaltrials.gov) -  Apr 28, 2022   
    P2,  N=402, Not yet recruiting, 
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Journal:  Variable-heavy (VH) families influencing IgA1&2 engagement to the antigen, FcαRI and superantigen proteins G, A, and L. (Pubmed Central) -  Apr 28, 2022   
    On their interactions with antigen-Her2 and superantigens PpL, SpG and SpA, PpL was found to sterically hinder Her2 antigen binding with unexpected findings of IgAs binding SpG at the CH2-3 region alongside SpA interacting with IgAs at the CH1. Although the VH3 framework (FWR) is commonly used in CDR grafting, we found the VH1 framework (FWR) to be a possible alternative when grafting IgA1 and 2 owing to its stronger binding to antigen Her2 and weaker interactions to superantigen Protein L and A. These findings lay the foundation to understanding the interactions between IgAs and microbial superantigens, and also guide the engineering of IgAs for future antibody applications and targeting of superantigen-producing microbes.
  • ||||||||||  Review, Journal:  Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review. (Pubmed Central) -  Apr 28, 2022   
    In the metastatic setting, prognosis has improved greatly with the use of anti-HER2 drugs such as trastuzumab, pertuzumab, and trastuzumab-emtansine...Systemic treatment of brain metastases in HER2-positive patients and the role of endocrine-based treatment for patients with hormone receptor (HR) positive disease remain areas of research interest. This article will review the current approach to systemic management of metastatic HER2-positive breast cancer in Canada, and present novel treatments that may be available in the near future.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Trial completion:  BrUOG 308: Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer. (clinicaltrials.gov) -  Apr 28, 2022   
    P2,  N=32, Completed, 
    This review paper discusses the current treatment options and presents a practical treatment sequencing algorithm in the context of the Canadian landscape. Active, not recruiting --> Completed
  • ||||||||||  Trial completion date, Trial primary completion date:  Testing a New Imaging Agent to Identify Cancer (clinicaltrials.gov) -  Apr 28, 2022   
    P1,  N=20, Recruiting, 
    Active, not recruiting --> Completed Trial completion date: Nov 2022 --> Nov 2024 | Trial primary completion date: Nov 2022 --> Nov 2024
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Nivolumab with chemotherapy as neoadjuvant treatment for inflammatory breast cancer. () -  Apr 28, 2022 - Abstract #ASCO2022ASCO_3392;    
    P2
    Addition of nivolumab to neoadjuvant therapy was tolerable and safe and demonstrated anti-tumor activity in IBC with high pCR rate in this pilot study. This supports further investigation of the role of checkpoint inhibitors in treatment of IBC.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial. (Available On Demand; 386b) -  Apr 28, 2022 - Abstract #ASCO2022ASCO_3321;    
    P2
    Clinically, pembrolizumab (K)-mediated ICI plus HER2-directed therapy with trastuzumab (H) was safe and demonstrated modest activity in H-resistant HER2-positive (HER2+) metastatic breast cancer...Moreover, the synergy of H and K with paclitaxel (T) may overcome the need for dual HER2-blockade with H plus pertuzumab (P)...Secondary end points include pCR rate by ypT0ypN0 and ypT0/Tis, residual cancer burden index, event free survival, breast conserving surgery rate, safety and overall survival. Exploratory correlative studies will characterize potential immune biomarkers predictive of efficacy and/or toxicity.